RecruitingNCT06673043

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study

Sponsor

AstraZeneca

Enrollment

100 participants

Start Date

Feb 28, 2025

Study Type

OBSERVATIONAL

Conditions

Lupus Erythematosus, Systemic

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Anifrolumab for people with lupus erythematosus, systemic. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnifrolumab

Anifrolumab 300 mg concentrate for solution for infusion

Locations(11)

Research Site

Bydgoszcz, Poland

Research Site

Bytom, Poland

Research Site

Gdansk, Poland

Research Site

Katowice, Poland

Research Site

Krakow, Poland

Research Site

Lodz, Poland

Research Site

Lublin, Poland

Research Site

Poznan, Poland

Research Site

Rzeszów, Poland

Research Site

Warsaw, Poland

Research Site

Wroclaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06673043

Related Trials

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT0720112911 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

Trial of Belimumab in Early Lupus

NCT035438391 location

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT0689793018 locations

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496169 locations